Support PenkeMerck & Co. Inc - Trending symbols
Latest News of Merck & Co. Inc
| Date | Title | Read |
|---|---|---|
| 2025-09-11 19:42 | Merck (MRK) Announces Positive Phase 3 Results For 21-Valent Pneumococcal Vaccine | Read |
| 2025-09-10 20:33 | US drugmaker scraps plans for £1bn UK research centre | Read |
| 2025-09-10 06:59 | Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating | Read |
| 2025-09-05 20:17 | Companies tap US bond market for nearly $70 billion, starting September on a busy note | Read |
| 2025-09-05 11:50 | Lyophilized Injectable Drugs Market Report 2025-2033 | R&D Efforts to Improve Safety and Reconstitution Time, Alongside Expanding CDMO Services and Emerging Market Contributions | Read |
| 2025-08-19 19:29 | Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation | Read |
| 2025-08-19 17:37 | MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer | Read |
| 2025-08-17 08:30 | Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial | Read |
| 2025-08-14 01:05 | China pharma firms turn to local reagent suppliers to cut costs and delivery times | Read |
Trends
| 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Other Income Expense Net | 119,000 | 190,000 | 309,000 | -305,000 | 4,000 | 166,000 | 170,000 | -487,000 | -317,000 | |
| Tax Provision | 2,559,497 | 1,706,331 | 4,265,828 | -972,092 | 3,293,736 | 1,204,773 | 4,498,509 | -8,738,483 | -4,239,974 | |
| Income before Tax | 4,487,000 | -904,000 | 3,583,000 | -70,000 | 3,513,000 | 137,000 | 3,650,000 | -8,985,000 | -5,335,000 | |
| Net Income | 3,944,000 | -696,000 | 3,248,000 | -231,000 | 3,017,000 | -196,000 | 2,821,000 | -8,796,000 | -5,975,000 | |
| EBITDA | 5,067,000 | -961,000 | 4,106,000 | -619,000 | 3,487,000 | 319,000 | 3,806,000 | -8,818,000 | -5,012,000 | |
| Operating Income | 5,067,000 | -961,000 | 4,106,000 | -668,000 | 3,438,000 | 873,500 | 4,311,500 | -9,474,500 | -5,163,000 | |
| Net Income from Continuing Operations | 3,949,000 | -696,000 | 3,253,000 | -235,000 | 3,018,000 | -193,000 | 2,825,000 | -8,797,000 | -5,972,000 | |
| Net Income Applicable to Common Shares | 3,944,000 | -696,000 | 3,248,000 | -231,000 | 3,017,000 | -196,000 | 2,821,000 | -8,796,000 | -5,975,000 |
Comments
How you think about this?